Primary IgA Nephropathy Clinical Trials in Guangzhou, Guangdong
2 recruitingGuangzhou, Guangdong, China
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Guangdong Hengrui Pharmaceutical Co., Ltd84 enrolled2 locationsNCT07354932
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462